Clinical Value of Schiller Test and HPV Examination for Cervical Intraepithelial Neoplasia

Abstract

Abstract: Objective To explore and analyze the clinical values of Schiller test and human papilloma virus (HPV) in detecting cervical intraepithelial neoplasia. Method From June 2021 to December 2022, 92 cases of patients with cervical intraepithelial neoplasia who were diagnosed and treated at Xinjiang Production and Construction Corps 13th Division of Hongxing Hospital were selected as the research subjects. All patients were underwent Schiller test and high-risk HPV examination, as well as pathological examination were detected. And the correlation of the examination were determined. Result The pathological diagnosis showed CIN1 grade in 56 cases, CIN2 grade in 24 cases, CIN3 grade in 6 cases, and cervical cancer in 6 cases in the 92 cases. The total positive rates of Schiller test were 45.65% (42/92), and the positive rates of Schiller test for CIN1, CIN2, CIN3, and cervical cancer patients were 24.07%, 66.67%, 83.33%, and 100.00%, respectively, and differences among them were statistically significant (P<0.05). The total positive rates of HPV-16 and HPV-18 were 58.70% (54/92) and 60.87% (56/92), respectively. The total positive rates of HPV-16 and HPV-18 in CIN1, CIN2, CIN3, and cervical cancer patients were 24.07%, 66.67%, 83.33%, and 100.00%, respectively, and differences among them were statistically significant (P<0.05). The positive rates of HPV-16 and HPV-18 in Schiller test positive patients were 90.48% and 95.23%, respectively, which were significantly higher than the 32.00% and 32.00% of Schiller test negative patients (P<0.05). Spearman correlation analysis showed there were correlation between Schiller test positivity, HPV-16 positivity, and HPV-18 positivity in patients with cervical intraepithelial neoplasia (P<0.05). Conclusion The positive diagnostic rate of Schiller test in cervical intraepithelial neoplasia needs to be improved, often accompanied by HPV-16 and HPV-18 positivity. Schiller test for cervical intraepithelial neoplasia is correlated with HPV test results, and has good clinical application value.

Key words: Schiller test, cervical intraepithelial neoplasia, human papillomavirus, relevance, cervical carcinoma

CLC Number:

R737.33

Ru Xiao-cui, Li Yong-fang. Clinical Value of Schiller Test and HPV Examination for Cervical Intraepithelial Neoplasia[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(7): 160-163.

References

[1] 孔北华. 规范诊断程序明确诊断标准——《子宫颈癌诊断》标准解读[J].中国卫生标准管理,2013,4(10):4-7.
[2] 卢珍. 宫颈高级别上皮内瘤变病人宫颈锥切术后复发危险因素分析[J].蚌埠医学院学报,2023,48(2):230-232.
[3] 李林臣,雷彦,韩会贤,等.LncRNA SNHG12在宫颈癌中的表达及其与高危型HPV感染的相关性研究[J].临床和实验医学杂志,2023,22(3):289-292.
[4] 王强珍. 血清TFF3、AIF-1和S100-A11水平在宫颈癌早期诊断和预后评估中的临床价值[J].检验医学与临床,2023,20(2):198-202.
[5] 黎卓涵,金海鸿,艾春玲,等.阴道镜下宫颈活检对宫颈上皮内瘤变的诊断价值探讨[J].中国实验诊断学,2023,27(1):40-44.
[6] 周颖,焦薇.宫颈高级别鳞状上皮内病变患者冷刀锥切术后发生切缘阳性的因素分析[J].贵州医科大学学报,2023,48(1):82-86.
[7] 刘佳敏,周明,温丹婷,等.清毒洗液治疗宫颈HR-HPV持续感染的临床疗效研究[J].广州中医药大学学报,2023,40(1):89-94.
[8] 张博,柳鑫.人乳头瘤病毒多重感染与宫颈癌前病变及宫颈癌关系的研究进展[J].中国性科学,2023,32(2):83-87.
[9] 杨颖,韦玉姣,韦桂红.高危型人乳头瘤病毒持续感染与阴道微生态环境及宫颈病变的相关性[J].中国热带医学,2023,23(2):151-156.
[10] 吕春亮,夏金多,闫萍,等.衡水地区宫颈病变筛查人群HPV感染基因型、阴道清洁度与宫颈病变程度的关系[J].山东医药,2023,63(4):79-81.
[11] 木朝宇,张晓梅,范德胜,等.高危型HPV感染亚型分布及其与宫颈病变和宫颈癌的关系[J].蚌埠医学院学报,2023,48(1):130-134.
[12] 田丽,刘京,李艳青,等.完带汤加减对HPV感染合并低度宫颈上皮内瘤变患者疾病转归及局部炎症的影响[J].陕西中医,2023,44(1):33-36.
[13] 于皓,吕莹莹,刘影,等.HPV持续感染及HPV E6/E7 mRNA表达与宫颈上皮内瘤变患者阴道微环境的关系[J].中华医院感染学杂志,2023,33(7):1080-1084.
[14] 陈苗,高丽,张婷,等.1357例宫颈上皮内瘤变临床特征及阴道镜图像的诊断意义[J].中国妇幼健康研究,2023,34(2):59-63.
[15] 岳彩霞,梁文华,张秉虹,等.宫颈癌患者人乳头瘤病毒感染情况及STING、ZEB1蛋白水平分析[J].中国微生态学杂志,2023,35(1):69-72.
[16] 王静,杜欣,黄燕明,等.宫颈癌高危型HPV感染的影响因素与ERK1/2信号通路关键因子[J].中华医院感染学杂志,2023,33(4):593-597.
[17] 胡森阳,唐雪,秦永,等.渝东南地区宫颈上皮内病变及宫颈癌患者HPV亚型分布关系[J].中国妇幼保健,2023,38(3):404-407.
[18] 柯善英,刘庆.Th1/Th2细胞因子在不同宫颈上皮内瘤变程度及宫颈癌患者血清中的表达水平及其临床意义[J].医学临床研究,2023,40(2):287-289.
[19] 张丽芳,欧阳小娟,余英豪,等.人乳头瘤病毒多基因亚型与病毒载量同步检测在子宫颈病理诊断中的应用[J].临床与实验病理学杂志,2022,38(3):350-353.
[20] 孔令华,肖晓萍,万茹,等.ThinPrep玻片扫描分析影像系统在子宫颈细胞学中的临床应用[J].协和医学杂志,2022,13(4):613-619.